Health Care Cos. Slide Amid High-Risk Concerns -- Health Care Roundup
Health care companies slid as traders retreated from high-risk issues. Shares of obesity-drug maker Novo Nordisk and Hims & Hers Health, the compounding pharmacy seeking to compete with the ...
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
The daily pill that regrows thicker, fuller hair FAST... and boosts your confidence in the bedroom
SHOPPING: Give yourself the gift of improved sense of self with the once-a-day treatment that contains ingredients to support ...
Hims & Hers Health: Developing A Better Understanding
Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...
Hims & Hers to keep offering compounded Ozempic, Wegovy, WSJ reports
The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...
STAT6d
Pharmalittle: We’re reading about copycat weight loss drugs, ADHD prescriptions spiking, and more
The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...